Cargando…
Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?
The identification of certain genomic alterations (EGFR, ALK, ROS1, BRAF) or immunological markers (PD-L1) in tissues or cells has led to targeted treatment for patients presenting with late stage or metastatic lung cancer. These biomarkers can be detected by immunohistochemistry (IHC) and/or by mol...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876645/ https://www.ncbi.nlm.nih.gov/pubmed/29534030 http://dx.doi.org/10.3390/cancers10030070 |
_version_ | 1783310553783992320 |
---|---|
author | Hofman, Véronique Lassalle, Sandra Bence, Coraline Long-Mira, Elodie Nahon-Estève, Sacha Heeke, Simon Lespinet-Fabre, Virginie Butori, Catherine Ilié, Marius Hofman, Paul |
author_facet | Hofman, Véronique Lassalle, Sandra Bence, Coraline Long-Mira, Elodie Nahon-Estève, Sacha Heeke, Simon Lespinet-Fabre, Virginie Butori, Catherine Ilié, Marius Hofman, Paul |
author_sort | Hofman, Véronique |
collection | PubMed |
description | The identification of certain genomic alterations (EGFR, ALK, ROS1, BRAF) or immunological markers (PD-L1) in tissues or cells has led to targeted treatment for patients presenting with late stage or metastatic lung cancer. These biomarkers can be detected by immunohistochemistry (IHC) and/or by molecular biology (MB) techniques. These approaches are often complementary but depending on, the quantity and quality of the biological material, the urgency to get the results, the access to technological platforms, the financial resources and the expertise of the team, the choice of the approach can be questioned. The possibility of detecting simultaneously several molecular targets, and of analyzing the degree of tumor mutation burden and of the micro-satellite instability, as well as the recent requirement to quantify the expression of PD-L1 in tumor cells, has led to case by case development of algorithms and international recommendations, which depend on the quality and quantity of biological samples. This review will highlight the different predictive biomarkers detected by IHC for treatment of lung cancer as well as the present advantages and limitations of this approach. A number of perspectives will be considered. |
format | Online Article Text |
id | pubmed-5876645 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-58766452018-04-09 Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients? Hofman, Véronique Lassalle, Sandra Bence, Coraline Long-Mira, Elodie Nahon-Estève, Sacha Heeke, Simon Lespinet-Fabre, Virginie Butori, Catherine Ilié, Marius Hofman, Paul Cancers (Basel) Review The identification of certain genomic alterations (EGFR, ALK, ROS1, BRAF) or immunological markers (PD-L1) in tissues or cells has led to targeted treatment for patients presenting with late stage or metastatic lung cancer. These biomarkers can be detected by immunohistochemistry (IHC) and/or by molecular biology (MB) techniques. These approaches are often complementary but depending on, the quantity and quality of the biological material, the urgency to get the results, the access to technological platforms, the financial resources and the expertise of the team, the choice of the approach can be questioned. The possibility of detecting simultaneously several molecular targets, and of analyzing the degree of tumor mutation burden and of the micro-satellite instability, as well as the recent requirement to quantify the expression of PD-L1 in tumor cells, has led to case by case development of algorithms and international recommendations, which depend on the quality and quantity of biological samples. This review will highlight the different predictive biomarkers detected by IHC for treatment of lung cancer as well as the present advantages and limitations of this approach. A number of perspectives will be considered. MDPI 2018-03-13 /pmc/articles/PMC5876645/ /pubmed/29534030 http://dx.doi.org/10.3390/cancers10030070 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hofman, Véronique Lassalle, Sandra Bence, Coraline Long-Mira, Elodie Nahon-Estève, Sacha Heeke, Simon Lespinet-Fabre, Virginie Butori, Catherine Ilié, Marius Hofman, Paul Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients? |
title | Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients? |
title_full | Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients? |
title_fullStr | Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients? |
title_full_unstemmed | Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients? |
title_short | Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients? |
title_sort | any place for immunohistochemistry within the predictive biomarkers of treatment in lung cancer patients? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876645/ https://www.ncbi.nlm.nih.gov/pubmed/29534030 http://dx.doi.org/10.3390/cancers10030070 |
work_keys_str_mv | AT hofmanveronique anyplaceforimmunohistochemistrywithinthepredictivebiomarkersoftreatmentinlungcancerpatients AT lassallesandra anyplaceforimmunohistochemistrywithinthepredictivebiomarkersoftreatmentinlungcancerpatients AT bencecoraline anyplaceforimmunohistochemistrywithinthepredictivebiomarkersoftreatmentinlungcancerpatients AT longmiraelodie anyplaceforimmunohistochemistrywithinthepredictivebiomarkersoftreatmentinlungcancerpatients AT nahonestevesacha anyplaceforimmunohistochemistrywithinthepredictivebiomarkersoftreatmentinlungcancerpatients AT heekesimon anyplaceforimmunohistochemistrywithinthepredictivebiomarkersoftreatmentinlungcancerpatients AT lespinetfabrevirginie anyplaceforimmunohistochemistrywithinthepredictivebiomarkersoftreatmentinlungcancerpatients AT butoricatherine anyplaceforimmunohistochemistrywithinthepredictivebiomarkersoftreatmentinlungcancerpatients AT iliemarius anyplaceforimmunohistochemistrywithinthepredictivebiomarkersoftreatmentinlungcancerpatients AT hofmanpaul anyplaceforimmunohistochemistrywithinthepredictivebiomarkersoftreatmentinlungcancerpatients |